Green tea extract tested to stop liver cancer before it starts

NCT ID NCT06015022

Recruiting now Prevention Sponsor: University of Texas Southwestern Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether a green tea compound called EGCG can lower the risk of liver cancer in people with cirrhosis. Researchers will give EGCG or a placebo to 60 adults with cirrhosis and no history of liver cancer. The goal is to see if EGCG reduces a biomarker linked to cancer risk.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Epigallocatechin gallate (EGCG), a compound from green tea
What this could lead to: If it works, this could point toward a simple, natural way to lower liver cancer risk in people with cirrhosis.
What could go wrong: This is a small, early-phase trial (60 people) testing a biomarker, not cancer itself. EGCG may not reduce actual cancer risk, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CIRRHOSIS, LIVER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver Liver Neoplasms hepatocellular carcinoma prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CIRRHOSIS, LIVER

Contacts and locations

Locations

UT Southwestern
RECRUITING

Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.